Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: Results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials

Current Opinion in Cardiology

Volumn 16, Issue 6, 2001, Pages 364-369

  McKay, Raymond G ^a   Boden, William E ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; PLACEBO; TIROFIBAN;

ADULT; AGED; CLINICAL TRIAL; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; HEART CATHETERIZATION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVASCULARIZATION; REVIEW; RISK BENEFIT ANALYSIS; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION;

ACETATES; CLINICAL TRIALS; ELECTROCARDIOGRAPHY; HEART CONDUCTION SYSTEM; HUMANS; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TYROSINE;

EID: 0035214859     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200111000-00009     Document Type: Review

References (38)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes
2. Thrombosis in ischemic heart disease
3. The role of plaque pathology in coronary thrombosis
4. Pathogenesis of acute ischemic coronary syndromes
5. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
6. Analysis of GP IIb/IIIa receptor number by quantification of 7E3 binding to human platelets
7. The platelet membrane glycoprotein IIb/IIIa complex
8. Cellular adhesion: GP IIb/IIIa as a prototype adhesion receptor
9. Role of fibrinogen alpha and gamma chain sites in platelet aggregation
10. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
11. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early revascularization
12. Development of eptifibatide
13. Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb/IIIa
14. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrelin therapy
15. Tirofiban, a nonpeptide inhibitor of the platelet glycoprotein IIb/IIIa receptor
16. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
17. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
18. Comparison of early invasive and conservative strategies in patients with unstable angina and non-ST segment elevation myocardial infarction treated with the glycoprotein IIb/IIIa inhibitor tirofiban
19. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina
20. International, randomized, controlled trial of lamifiban (platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina
21. Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: Rationale and design of the PARAGON B study
22. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status. The PARAGON-B troponin T substudy
23. Overview of clinical trial of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
24. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition
25. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina)
26. Cardiac troponin T levels for risk stratification in acute myocardial ischemia
27. Prognostic value of cardiac troponin T in unstable angina pectoris
28. Angiographic findings in patients with refractory unstable angina according to troponin T status
29. Clinical trials of the parenteral glycoprotein IIb/IIIa inhibitors: Considerations on the influence of dose selection on results
30. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
31. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention
32. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
33. Comparison of two platelet glycoprotein inhibitors, tirofiban and abciximab, for prevention of ischemic events with percutaneous coronary intervention
34. Bleeding complications of glycoproten IIb/IIIa receptor inhibitors
35. Risks and benefits of glycoprotein IIb/IIIa antagonists in acute coronary syndromes
36. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes
37. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q wave myocardial infarction. Results of the TIMI IIIB Trial
38. Outcomes in patients with acute non-Q wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy